Stock Performance & Trading Context
Q4 2025 Results Snapshot
IFF reported fourth-quarter 2025 net sales of $2.589 billion, down 7% year over year. On a comparable currency-neutral basis, sales increased 1%. Income before taxes totaled $22 million, compared with a loss in the prior-year period. Adjusted operating EBITDA was $437 million, with adjusted EBITDA margin of 16.9%. Comparable currency-neutral adjusted EBITDA rose 7%, driven mainly by productivity gains. Reported EPS came in at $0.07, while adjusted EPS (ex-amortization) was $0.80 per diluted share.
Q4 Segment Highlights
- Taste: Sales $588 million; adjusted EBITDA $94 million; margin 16.0%.
- Health & Biosciences: Sales $589 million; EBITDA $155 million; margin 26.3%.
- Scent: Sales $610 million; EBITDA $106 million; margin 17.4%.
- Food Ingredients: Sales $802 million; EBITDA $82 million; margin 10.2%.
Full-Year 2025 Financial Performance
IFF reported full-year net sales of $10.890 billion, a 5% decline year over year. Comparable currency-neutral sales increased 2%. Loss before taxes was $412 million. Adjusted operating EBITDA totaled $2.086 billion, with EBITDA margin of 19.2%. Comparable currency-neutral adjusted EBITDA grew 7%. Reported EPS was $(1.46), while adjusted EPS (ex-amortization) reached $4.20 per diluted share.
Cash Flow & Balance Sheet
- Operating cash flow: $850 million
- Free cash flow: $256 million
- Year-end net debt to credit-adjusted EBITDA stood at 2.6x.
- IFF ended 2025 with $590 million in cash and equivalents and total assets of $25.537 billion.
Outlook & Strategic Actions
The company launched a sale process for its Food Ingredients segment as part of portfolio optimization.
For 2026, IFF expects:
- Sales: $10.5B–$10.8B
- Adjusted EBITDA: $2.05B–$2.15B